Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Gynecologic Oncology
•
Pediatric Hematology/Oncology
•
FAQ
•
Medical Oncology
Is there a Mednet app?
Answer from: Radiation Oncologist at Community Practice
theMednet app is here! Follow these links to download it for your iOS and Android devices.
Sign In
or
Register
to read more
Answer from: Radiation Oncologist at Community Practice
As more hospitals improve their WiFi, I envision attendings and residents co-reviewing comments from theMednet in between patient visits. Looking forward to it.
Sign In
or
Register
to read more
1158
1166
Related Questions
What screening tools or signs do you use to predict if a cancer patient is near end-of-life?
What strategies do you find helpful in advanced care planning with patients/families who are very "miracle" centered?
In pediatric patients with Hodgkin lymphoma who have a partial response after chemotherapy and multiple disease sites above and below the diaphragm, how do you approach radiotherapy planning considering cumulative dose and toxicity?
In patients treated with the KEYNOTE A-18 regimen who later recur, would you rechallenge with immunotherapy again?
How would you advise a younger patient with residual/recurrent optic nerve meningioma, proceeding with radiotherapy, about the risks of malignant transformation or induction of other brain malignancies because of radiation?
What are your top takeaways from SGO 2025?
In platinum-refractory or multiply-relapsed NSGCT with 1–2 progressive sites and no good surgical option, is there a role for local radiotherapy (e.g., SBRT) to those sites?
Do you have concerns about the validity of the INTERLACE data, considering the long study recruitment period (10 years) and evolution of radiation techniques that have occurred during that time frame?
Does being on maintenance pembrolizumab change how you manage patients with partial metabolic response on PET/CT 3 months after chemoradiation for cervical cancer?
How have you incorporated ctDNA into the clinical management of patients with gynecologic cancers?